SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN)
BTRN 35.340.0%Nov 6 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (1156)12/11/2001 9:11:53 AM
From: Arthur Radley  Read Replies (3) of 1475
 
In anybodies book, this is impressive data IMO:

"Patients in both groups received identical numbers of CD4+ T cells. Nine patients received CD8-depleted DLI and did not develop GvHD. In contrast, six of nine patients who received non-depleted DLI subsequently developed significant acute GvHD. The estimated two-year relapse-free survival post BMT was 86% in the patients receiving CD8-depleted DLI, compared with 52% of patients receiving unselected DLI"
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News